Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ADC THERAPEUTICS SA

(ADCT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Sector Update: Health Care Stocks Ending Slightly Lower This Afternoon

08/26/2021 | 03:57pm EST


ę MT Newswires 2021
All news about ADC THERAPEUTICS SA
11/09Wolfe Research Starts ADC Therapeutics at Outperform with $44 Price Target
MT
11/09ADC Therapeutics to Participate in the Jefferies London Healthcare Conference - Form 6-..
PU
11/09ADC Therapeutics to Participate in the Jefferies London Healthcare Conference
BU
11/04ADC Therapeutics Announces Abstracts to be Presented at the 63rd ASH Annual Meeting - F..
PU
11/04ADC Therapeutics Announces Abstracts to be Presented at the 63rd ASH Annual Meeting
BU
11/02ADC Therapeutics Q3 Loss Widens, Beats Estimate
MT
11/02Purchase Agreement - Form 6-K
PU
11/02Earnings Flash (ADCT) ADC THERAPEUTICS SA Reports Q3 Loss $-0.59
MT
11/02ADC Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Upd..
BU
11/02ADC Therapeutics SA Reports Earnings Results for the Third Quarter and Nine Months Ende..
CI
More news
Analyst Recommendations on ADC THERAPEUTICS SA
More recommendations
Financials (USD)
Sales 2021 33,7 M - -
Net income 2021 -265 M - -
Net cash 2021 472 M - -
P/E ratio 2021 -6,22x
Yield 2021 -
Capitalization 1 647 M 1 647 M -
EV / Sales 2021 34,9x
EV / Sales 2022 13,9x
Nbr of Employees 208
Free-Float 48,6%
Chart ADC THERAPEUTICS SA
Duration : Period :
ADC Therapeutics SA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ADC THERAPEUTICS SA
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 21,46 $
Average target price 41,83 $
Spread / Average Target 94,9%
EPS Revisions
Managers and Directors
Christopher John Martin Chief Executive Officer & Director
Jennifer Creel Chief Financial Officer
Ron Squarer Chairman
Patrick van Berkel Senior Vice President-Research & Development
Joseph S. Camardo Chief Medical Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
ADC THERAPEUTICS SA-29.96%1 721
GILEAD SCIENCES, INC.19.58%87 393
BIONTECH SE310.30%80 545
REGENERON PHARMACEUTICALS31.23%66 288
WUXI APPTEC CO., LTD.26.31%65 499
VERTEX PHARMACEUTICALS-13.49%51 982